Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 12, 2006, Pages 1239-1249

  Li, Jian ming ^a   Gorechlad, John ^a   Larsen, Christian P ^b   Waller, Edmund K ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti CD154 monoclonal antibody; Costimulatory blockade; Graft versus host disease; Tolerance; Transplantation

Indexed keywords

BUSULFAN; CD11B ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL DEATH; CELL POPULATION; CELL VIABILITY; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MEGADOSE; EX VIVO STUDY; GRAFT RECIPIENT; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE;

ANIMALS; ANIMALS, CONGENIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; APOPTOSIS; BONE MARROW TRANSPLANTATION; BUSULFAN; CD40 LIGAND; CULTURE MEDIA, CONDITIONED; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; H-2 ANTIGENS; INTERFERON TYPE II; INTERLEUKIN-10; LEUKOCYTE TRANSFUSION; LEUKOCYTES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SPLEEN; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845277327     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.08.038     Document Type: Article

References (46)

1. Atkinson K., Champlin R., Ritz J., Fibbe W.E., Ljungman P., and Brenner M.K. Clinical Bone Marrow and Blood Stem Cell Transplantation. 3rd ed. (2004), Cambridge University Press, New York
2. Larsen C.P., Alexander D.Z., Hollenbaugh D., et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 61 (1996) 4-9
3. Deeg H.J., Klingemann H.G., Phillips G.L., and Van Zant G. A Guide to Blood and Marrow Transplantation. 3rd ed. (1999), Springer, New York
4. Durham M.M., Bingaman A.W., Adams A.B., et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 165 (2000) 1-4
5. Appelbaum F.R. Haematopoietic cell transplantation as immunotherapy. Nature 411 (2001) 385-389
6. Wekerle T., Kurtz J., Ito H., et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 6 (2000) 464-469
7. Blaha P., Bigenzahn S., Koporc Z., et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 101 (2003) 2886-2893
8. Prigozhina T.B., Gurevitch O., Elkin G., Morecki S., Yakovlev E., and Slavin S. CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells. Exp Hematol 31 (2003) 81-88
9. Taylor P.A., Lees C.J., Wilson J.M., et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 100 (2002) 3400-3407
10. Adams A.B., Durham M.M., Kean L., et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 167 (2001) 1103-1111
11. Taylor P.A., Friedman T.M., Korngold R., Noelle R.J., and Blazar B.R. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 99 (2002) 4601-4609
12. Kurtz J., Shaffer J., Lie A., Anosova N., Benichou G., and Sykes M. Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: evidence for anergy and deletion but not regulatory cells. Blood 103 (2004) 4336-4343
13. Seung E., Mordes J.P., Rossini A.A., and Greiner D.L. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J Clin Invest 112 (2003) 795-808
14. Wekerle T., Sayegh M.H., Hill J., et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 187 (1998) 2037-2044
15. Quesenberry P.J., Zhong S., Wang H., and Stewart M. Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice. Blood 97 (2001) 557-564
16. Markees T.G., Phillips N.E., Gordon E.J., et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 101 (1998) 2446-2455
17. Giver C.R., Montes R.O., Mittelstaedt S., et al. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Biol Blood Marrow Transplant 9 (2003) 616-632
18. Waller E.K., Ship A.M., Mittelstaedt S., et al. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. Blood 94 (1999) 3222-3233
19. Truitt R.L., Johnson B.D., Hanke C., Talib S., and Hearst J.E. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 163 (1999) 5145-5156
20. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88 (1996) 3230-3239
21. Li J.M., and Waller E.K. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 10 (2004) 540-551
22. Steinman R.M., Turley S., Mellman I., and Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191 (2000) 411-416
23. Li J.M., Giver C.R., and Waller E.K. Graft engineering using ex vivo methods to limit GvHD: fludarabine treatment generates superior GvL effects in allogeneic BMT. Exp Hematol 34 (2006) 895-904
24. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 8 (2002) 477-485
25. Vassal G., Deroussent A., Hartmann O., et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 50 (1990) 6203-6207
26. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16 (1995) 31-42
27. Albert M.L., Jegathesan M., and Darnell R.B. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2 (2001) 1010-1017
28. Liu K., Iyoda T., Saternus M., Kimura Y., Inaba K., and Steinman R.M. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196 (2002) 1091-1097
29. Heath W.R., Kurts C., Miller J.F., and Carbone F.R. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med 187 (1998) 1549-1553
30. Bittencourt M.C., Perruche S., Contassot E., et al. Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. Blood 98 (2001) 224-230
31. Stuart L.M., Lucas M., Simpson C., Lamb J., Savill J., and Lacy-Hulbert A. Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J Immunol 168 (2002) 1627-1635
32. Gao Y., Herndon J.M., Zhang H., Griffith T.S., and Ferguson T.A. Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis. J Exp Med 188 (1998) 887-896
33. Chen W., Frank M.E., Jin W., and Wahl S.M. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14 (2001) 715-725
34. Fadok V.A., Bratton D.L., Konowal A., Freed P.W., Westcott J.Y., and Henson P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101 (1998) 890-898
35. Ferguson T.A., Herndon J., Elzey B., Griffith T.S., Schoenberger S., and Green D.R. Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness. J Immunol 168 (2002) 5589-5595
36. Rulifson I.C., Szot G.L., Palmer E., and Bluestone J.A. Inability to induce tolerance through direct antigen presentation. Am J Transplant 2 (2002) 510-519
37. Lipscomb M.F., and Masten B.J. Dendritic cells: immune regulators in health and disease. Physiol Rev 82 (2002) 97-130
38. Maeda A., Schwarz A., Kernebeck K., et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol 174 (2005) 5968-5976
39. Monk N.J., Hargreaves R.E., Marsh J.E., et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 9 (2003) 1275-1280
40. Foy T.M., Shepherd D.M., Durie F.H., Aruffo A., Ledbetter J.A., and Noelle R.J. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med 178 (1993) 1567-1575
41. Taylor P.A., Lees C.J., Waldmann H., Noelle R.J., and Blazar B.R. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 98 (2001) 467-474
42. Van Maurik A., Fazekas de St Groth B., Wood K.J., and Jones N.D. Dependency of direct pathway CD4+ T cells on CD40-CD154 costimulation is determined by nature and microenvironment of primary contact with alloantigen. J Immunol 172 (2004) 2163-2170
43. Ildstad S.T., Chilton P.M., Xu H., Domenick M.A., and Ray M.B. Preconditioning of NOD mice with anti-CD8 mAb and costimulatory blockade enhances chimerism and tolerance and prevents diabetes, while depletion of {alpha}{beta}-TCR+ and CD4+ cells negates the effect. Blood 105 (2005) 2577-2584
44. Pulendran B., Lingappa J., Kennedy M.K., et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol 159 (1997) 2222-2231
45. Ghansah T., Paraiso K.H., Highfill S., et al. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell response. J Immunol 173 (2004) 7324-7330
46. Wang J.W., Howson J.M., Ghansah T., et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 295 (2002) 2094-2097